Novo Nordisk shareholders are publicly urging the pharmaceutical giant to pursue acquisitions and new drug development. Investors aim to decrease the company's significant reliance on its blockbuster drug, Ozempic.
The call for diversification precedes the company's Capital Markets Day scheduled for September 21. Major stakeholders cite long-term risks associated with depending heavily on a single product line.
Analysts and investment managers demand a clear strategy to ensure sustainable future growth. Management faces increasing pressure to present proactive measures during the upcoming event.